@drsalomemasghatimd's testosterone therapy claims, fact-checked

What did @drsalomemasghatimd actually say?

The creator made three main points about testosterone replacement therapy for women. First, estrogen should be optimized before starting testosterone because estrogen affects "the sensitivity of your testosterone receptors." Second, she recommended reversible delivery methods, specifically creams or gels, over pellets or injections, arguing they offer "better control over the levels" and faster reversal when stopped. The third point appears to have been cut from the transcript.

These are practical clinical recommendations, not fringe ideas. She is not selling a supplement stack or promising a cure. The framing is cautious and focuses on patient control, which is worth noting in a space full of overclaiming. The claims are specific enough to fact-check meaningfully.

Does the science back this up?

Partially, yes. The estrogen-testosterone receptor interaction is real and documented, though the language she used slightly oversimplifies the mechanism. The reversibility argument for gels and creams over pellets has solid practical support in clinical literature.

On the estrogen-receptor point: estrogen does modulate androgen receptor expression in certain tissues. Research by Wierman et al. (2014, Journal of Clinical Endocrinology and Metabolism) reviewing female androgen insufficiency noted that estrogen status influences androgen bioavailability and tissue response, partly through sex hormone-binding globulin and receptor-level effects. That said, calling it "sensitivity of your testosterone receptors" is a loose interpretation. The mechanism involves SHBG, free testosterone fractions, and tissue-specific receptor expression rather than a simple on/off sensitivity switch.

On reversibility: pellets dissolve over three to six months and cannot be removed once inserted. Gels and creams clear the system within days of stopping. A 2019 review by Glaser and Dimitrakakis in Maturitas confirmed that pellet-related side effects, including supraphysiologic testosterone levels, can persist for months. That is a real clinical limitation she is right to flag.

What did they get wrong (or right)?

She got the reversibility argument right, and that deserves direct credit. Pellet therapy for women carries a documented risk of sustained elevated testosterone levels with no easy correction. Recommending cream or gel first is consistent with what most evidence-based practitioners do.

Where she oversimplified: the idea that low estrogen means testosterone simply "is not going to work" is too binary. Testosterone has androgen-receptor-mediated effects that do not depend entirely on estrogen optimization. Women with surgical menopause and low estrogen have still shown benefit from testosterone in libido trials, including the landmark APHRODITE study (Davis et al., 2008, New England Journal of Medicine). Estrogen status matters and influences outcomes, but framing it as a prerequisite for testosterone to function at all overstates the dependency.

The missing third point is also a problem. The video caption references adrenal health, DHEA, and pregnenolone as precursors, but none of that appears in the transcript. If she said it and it was cut, viewers are getting incomplete information. If she did not say it, the caption is doing clinical work the video is not actually doing.

What should you actually know?

Women considering testosterone therapy should understand a few things the video touches on but does not fully explain. Testosterone therapy for women is used off-label in the United States. The only FDA-approved testosterone product for women was withdrawn from the market in 2019. That does not mean the therapy is unsafe or ineffective, but it does mean the prescribing exists in a regulatory gray zone that patients should understand.

The Global Consensus Position Statement on testosterone in women (Dhillo et al., 2019, Journal of Clinical Endocrinology and Metabolism) supports testosterone use for hypoactive sexual desire disorder in postmenopausal women, with the caveat that physiologic, not supraphysiologic, dosing is the goal. The statement also emphasizes that long-term safety data beyond two years are limited.

Estrogen status is a legitimate clinical consideration before starting testosterone, particularly in perimenopausal or postmenopausal women where both hormones are in flux. But it is a factor to weigh, not a hard gate that blocks testosterone from working at all. Work with a provider who monitors both hormones with bloodwork, not just symptom reports.